Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

706 articles

Showing 1–11 of 11 articles · Keyword: Tumor microenvironment Clear keyword

Journal of controlled release : official journal of the Controlled Release Society2026ReviewNon-viral Gene DeliveryDrug Delivery

1. Stimuli-responsive CRISPR-based genome editing delivery system for cancer treatment: A review of fundamentals and applications

Jiang Y, Sun R, Zhang J, Wang C, Chen X, Wu D

Cancer remains a leading cause of mortality worldwide. Conventional modalities, namely surgery, radiotherapy, chemotherapy, and immunotherapy, continue to face substantial limitations. The advent of gene therapy, particularly CRISPR-based genome editing, offers new opportunities to overcome these barriers.

Read the article
The Journal of pharmacy and pharmacology2026ReviewDrug Delivery

2. Overcoming oxaliplatin resistance and toxicity in colorectal cancer: the emerging role of lipid-based nanocarriers

Chauhan A, Kumar M, Awasthi A

To provide a comprehensive overview of lipid-based nanocarriers for oxaliplatin (OXA) delivery in colorectal cancer (CRC), with emphasis on their potential to improve pharmacokinetics, enhance tumour accumulation, enable controlled drug release, and overcome OXA resistance. Relevant literature on OXA, CRC…

Read the article
International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery

3. Next-Generation Cancer Nanovaccines: Reprogramming the Tumor Microenvironment from Rational Design Toward Clinical Translation

Tabibzadeh S, Meng F, Asghariazar V, Safarzadeh E, Esmaeili A, Ten Hagen Tlm, Et Al.

Cancer vaccines have emerged as a promising immunotherapeutic strategy for inducing durable and tumour-specific immune responses; however, their clinical efficacy remains limited by poor antigen immunogenicity, inefficient delivery, tumor heterogeneity, and the highly immunosuppressive tumor microenvironment (TME).

Read the article
Acta pharmaceutica Sinica. B2026ResearchNon-viral Gene DeliveryDrug Delivery

4. Targeting cancer-associated neutrophils with biomimetic nano-vaccines loaded with mRNA can enhance the efficacy of immunotherapy for hepatocellular carcinoma

Li S, Zhang Y, Han Y, Zhao M, Wang Y, Lu J, Et Al.

Neutrophils exhibit significant plasticity within the tumor microenvironment (TME), such as promoting immune suppression, tumor growth, and metastasis. Although various nano drug delivery systems targeting neutrophils have been developed based on their tumor chemotaxis, few studies have focused on designing…

Read the article
Frontiers in pharmacology2026ReviewDrug Delivery

5. Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery

Ding L, Staskiewicz A, Kao J, Wang X

Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)…

Read the article
Expert opinion on drug delivery2026ReviewNon-viral Gene Delivery

6. Microenvironment-guided design of non-viral gene delivery systems: from biological cues to therapeutic translation

Mohammad Gholinia Sarpoli L, Hamblin Mr, Ebrahimifard M

Non-viral gene delivery systems offer adaptable alternatives to viral vectors for gene therapy. Nevertheless, their clinical translation remains limited by biological barriers and the pathological tissue microenvironment. Tumors exhibit alterations in the tissue microenvironment, including extracellular acidosis…

Read the article
Frontiers in immunology2026ReviewDrug Delivery

7. Natural killer cell-derived extracellular vesicles in cancer: mediators of intercellular communication and tumor immune signaling

Liu J, Yang Y, Zhang W, Liu J, Yu Y, Song Y, Et Al.

Natural killer (NK) cells are essential components of innate immunity and play a pivotal role in tumor surveillance through direct cytotoxicity and immune regulation. In recent years, NK-cell-derived extracellular vesicles (NK-EVs) have emerged as a promising cell-free therapeutic modality that preserves key…

Read the article
The Journal of pharmacology and experimental therapeutics2026ResearchNon-viral Gene DeliveryDrug Delivery

8. Bioactivatable conjugated nanocarriers for synergistic mRNA-mediated cancer immunotherapy

Nazir N, Gajjar Tb, Hanumanthayya M, Bainsal N, Singhal D, Smerat A, Et Al.

mRNA immunotherapy holds transformative potential in oncology, yet single-agent approaches frequently fail against immunosuppressive tumor microenvironments (TMEs). Bioactivatable co-delivery of immunogenic chemotherapy alongside mRNA offers mechanistically synergistic advantages, yet coformulation of hydrophobic…

Read the article
International journal of molecular sciences2026ReviewNon-viral Gene DeliveryDrug Delivery

9. Recent Advances in Lipid Nanoparticles for Cancer Vaccines: From Antigen Delivery to Personalized Immunotherapy

Rachamala Hk, Angom Rs, Marepally S

In recent years, lipid nanoparticles (LNPs) have shown great promise as highly flexible delivery systems for cancer vaccines, which enable effective cargo delivery and allow for controlling their distribution, cell-targeting ability and immunogenicity. Innovations in ionizable lipid chemistry, biodegradable…

Read the article
Frontiers in oncology2026ReviewDrug Delivery

10. Extracellular vesicles as biomimetic platforms for photo-assisted cancer therapy: evolution from synthetic nanocarriers to engineered therapeutic systems

Beaugé L, Ibarra Le

Photo-assisted therapies have emerged as promising strategies for cancer treatment by combining localized tumor ablation with the induction of systemic antitumor immune responses. Despite encouraging preclinical and clinical advances, their therapeutic efficacy remains limited by the unfavorable pharmacokinetics…

Read the article
International journal of nanomedicine2026ReviewDrug Delivery

11. Macrophage-Based Nanoplatforms for Tumor-Targeted Drug Delivery and Cancer Immunomodulation: Extracellular Vesicles, Membrane-Coated Nanoparticles, and Live Cells

Li X, Yu Y, Xie Y, He P, Chen Y, Guo Z, Et Al.

Macrophages are highly plastic immune cells with tumor-homing capacity and immunomodulatory functions, making macrophage-based nanoplatforms attractive for cancer immunotherapy. Macrophage-based nanoplatforms include macrophage-derived extracellular vesicles (EVs), macrophage membrane-coated nanoparticles, and live…

Read the article
Articles | Brilliant Blue Biosciences